Analysed UPSTREAM BIO INC (UPB:NASDAQ) News Sources
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
17-04-2026
yahoo.com
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
13-05-2026
yahoo.com
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
18-05-2026
yahoo.com
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
03-06-2026
yahoo.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
08-06-2026
yahoo.com
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
14-06-2026
yahoo.com
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
25-06-2026
yahoo.com
What is the current price of UPSTREAM BIO INC (UPB:NASDAQ)?
The current price of UPSTREAM BIO INC (UPB:NASDAQ) is $6.31.
UPSTREAM BIO INC (UPB:NASDAQ) absolute price change since previous trading day?
The absolute price change of UPSTREAM BIO INC (UPB:NASDAQ) since the previous trading day is $-0.26.
UPSTREAM BIO INC (UPB:NASDAQ) percentage price change since previous trading day?
The percentage price change of UPSTREAM BIO INC (UPB:NASDAQ) since the previous trading day is -3.9574%.
What is the most recent average sentiment score for UPSTREAM BIO INC (UPB:NASDAQ)?
The most recent average sentiment score for UPSTREAM BIO INC (UPB:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for UPSTREAM BIO INC (UPB:NASDAQ)?
The most recent sentiment for UPSTREAM BIO INC (UPB:NASDAQ) is .
SEC-8K** Filing Available For UPSTREAM BIO INC (UPB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.